233 related articles for article (PubMed ID: 7493373)
1. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.
Wong JY; Williams LE; Yamauchi DM; Odom-Maryon T; Esteban JM; Neumaier M; Wu AM; Johnson DK; Primus FJ; Shively JE
Cancer Res; 1995 Dec; 55(23 Suppl):5929s-5934s. PubMed ID: 7493373
[TBL] [Abstract][Full Text] [Related]
2. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
4. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
6. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.
Wong JY; Somlo G; Odom-Maryon T; Williams LE; Liu A; Yamauchi D; Wu AM; Yazaki P; Wilczynski S; Shively JE; Forman S; Doroshow JH; Raubitschek AA
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3224s-3231s. PubMed ID: 10541368
[TBL] [Abstract][Full Text] [Related]
7. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
Wong JY; Chu DZ; Williams LE; Yamauchi DM; Ikle DN; Kwok CS; Liu A; Wilczynski S; Colcher D; Yazaki PJ; Shively JE; Wu AM; Raubitschek AA
Clin Cancer Res; 2004 Aug; 10(15):5014-21. PubMed ID: 15297402
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
Wong JY; Chu DZ; Williams LE; Liu A; Zhan J; Yamauchi DM; Wilczynski S; Wu AM; Yazaki PJ; Shively JE; Leong L; Raubitschek AA
Cancer Biother Radiopharm; 2006 Apr; 21(2):88-100. PubMed ID: 16706629
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans.
Odom-Maryon TL; Williams LE; Chai A; Lopatin G; Liu A; Wong YC; Chou J; Clarke KG; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1959-66. PubMed ID: 9430477
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2.
Juweid ME; Sharkey RM; Behr T; Swayne LC; Dunn R; Siegel J; Goldenberg DM
J Nucl Med; 1996 Sep; 37(9):1504-10. PubMed ID: 8790202
[TBL] [Abstract][Full Text] [Related]
12. Intrapatient consistency of imaging biodistributions and their application to predicting therapeutic doses in a phase I clinical study of 90Y-based radioimmunotherapy.
Clarke KG; Odom-Maryon TL; Williams LE; Liu A; Lopatin G; Chou J; Farino GM; Raubitschek AA; Wong JY
Med Phys; 1999 May; 26(5):799-809. PubMed ID: 10360545
[TBL] [Abstract][Full Text] [Related]
13. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM
Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773
[TBL] [Abstract][Full Text] [Related]
14. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
[TBL] [Abstract][Full Text] [Related]
16. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
Vuillez JP; Kraeber-Bodéré F; Moro D; Bardiès M; Douillard JY; Gautherot E; Rouvier E; Barbet J; Garban F; Moreau P; Chatal JF
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3259s-3267s. PubMed ID: 10541373
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.
Sharkey RM; Kaltovich FA; Shih LB; Fand I; Govelitz G; Goldenberg DM
Cancer Res; 1988 Jun; 48(11):3270-5. PubMed ID: 3365705
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
[TBL] [Abstract][Full Text] [Related]
20. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]